Company intelligence / Profile preview

Felis Foundation

South San Francisco, California, United Statesoverseas-association.eu ↗

Ownership: Private
Development stage: Other

Overview

Felix Biotechnology is developing inhalable phage therapies targeting chronic, drug-resistant Pseudomonas aeruginosa infections in cystic fibrosis. Their lead program is supported by the Cystic Fibrosis Foundation and based on technology licensed from Yale University. Early-stage clinical evaluation is ongoing at Yale, with preclinical work funded to address bacterial resistance—a key limitation of traditional phage therapy.

Therapeutic areas: Infectious Diseases
Modalities: Phage therapyBiologic
Industry: Biotech

Partnerships

Cystic Fibrosis Foundation (Therapeutics Development Award/investment)

Beyond the preview

Go deeper on Felis Foundation.

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on Felis Foundation.

Explore the full profile